4d Molecular Therapeutics(NASDAQ) FDMT

4D Molecular Therapeutics develops gene therapies for serious eye and lung diseases. Its treatments aim to help people with vision loss or chronic lung conditions. The company uses engineered viruses to deliver healthy genes to affected cells.

Gene Therapy in Action: What 4D Offers

• Retina Therapies: Treatments for vision loss, including wet age-related macular degeneration and inherited retinal diseases. (100% of 2025 revenue from collaboration agreements, not product sales)
• Lung Disease Therapies: Gene therapies for cystic fibrosis and alpha-1 antitrypsin deficiency, targeting patients with chronic lung conditions. (No direct product sales revenue)
• Cardiology Pipeline: Early-stage research for heart-related genetic diseases, not yet generating revenue.
• Collaboration Agreements: Licensing and research partnerships, such as with Otsuka Pharmaceutical and Cystic Fibrosis Foundation, drive all current revenue.
• Proprietary AAV Platform: Uses engineered viruses (AAVs) to deliver genes precisely to target tissues.

Growth and Expansion: The 4D Timeline Shuffle

• 2025: Signed major collaboration with Otsuka Pharmaceutical for Asia-Pacific rights to lead eye therapy.
• 2025: Completed enrollment for the first Phase 3 clinical trial in wet age-related macular degeneration; enrollment for the second Phase 3 trial was ongoing.
• 2025: Secured additional funding from Cystic Fibrosis Foundation for lung disease program.
• 2025: Reduced workforce by 25% to focus on late-stage programs.
• 2024-2025: Raised capital through public offerings and at-the-market equity sales.

What Makes 4D Stand Out (Without the Lab Coat)

4D uses a proprietary platform to design gene delivery tools that target specific tissues. Its business model relies on partnerships and licensing, not product sales. The company manages its own manufacturing and supplements capacity with outside contractors.

Five Things You Need to Know

• Revenue was $85.2 million in FY 2025, up approximately 230,159% from FY 2024.
• All 2025 revenue came from collaboration and licensing, not product sales.
• Net loss was $140.1 million in FY 2025, improved from $160.9 million in FY 2024.
• Cash, cash equivalents, and marketable securities totaled $514 million at December 31, 2025.
• Otsuka Pharmaceutical accounted for 99.8% of 2025 revenue.

Bottom Line

4D Molecular Therapeutics has shifted from early research to late-stage clinical trials and major partnerships. The company remains focused on gene therapies for eye and lung diseases, with all revenue from collaborations.